By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GlycoMimetics, Inc. 

14915 Broschart Road, Suite 200

Rockville   Maryland  20850  U.S.A.
Phone: 301-738-1166 Fax:




Company News
GlycoMimetics, Inc. (GLYC) Appoints Scott Koenig Of MacroGenics (MGNX) To Board Of Directors 3/13/2017 8:12:24 AM
GlycoMimetics, Inc. (GLYC) Completes Enrollment Of Newly Diagnosed AML Patient Cohort In Phase II Clinical Trial Of GMI-1271 3/7/2017 8:36:41 AM
GlycoMimetics, Inc. (GLYC) To Present New Preclinical Data In Multiple Myeloma At AACR Annual Meeting 2017 3/2/2017 6:49:10 AM
GlycoMimetics, Inc. (GLYC) Reports Fourth Quarter And Year-End 2016 Results 3/1/2017 8:16:12 AM
GlycoMimetics, Inc. (GLYC)' GMI-1271 Continues To Yield High Remission Rates, Favorable Tolerability In Two Phase II Arms Of Ongoing Phase I/II Clinical Trial For AML 12/5/2016 11:19:32 AM
GlycoMimetics, Inc. (GLYC) To Present Preclinical Cancer Results At Society For Immunotherapy Of Cancer Meeting 11/8/2016 8:23:45 AM
GlycoMimetics, Inc. (GLYC) Reports Third Quarter 2016 Results And Progress In Clinical Development 11/4/2016 11:07:25 AM
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 1 Clinical Trial Of Drug Candidate GMI-1271 For Multiple Myeloma 9/14/2016 11:06:10 AM
GlycoMimetics, Inc. (GLYC) Initiates Dosing In Phase I Clinical Trial Of GMI-1359 9/6/2016 11:01:12 AM
GlycoMimetics, Inc. (GLYC) Announces Publication Of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack 8/16/2016 9:18:03 AM